{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:50:52Z","timestamp":1791823852866,"version":"4.3.4"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008523","name":"Center for Clinical and Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmunity is an increasingly recognized cause of encephalitis with a similar prevalence to that of infectious etiologies. Over the past decade there has been a rapidly expanding list of antibody biomarker discoveries that have aided in the identification and characterization of autoimmune encephalitis. As the number of antibody biomarkers transitioning from the research setting into clinical laboratories has accelerated, so has the demand and complexity of panel-based testing. Clinical laboratories are increasingly involved in discussions related to test utilization and providing guidance on which testing methodologies provide the best clinical performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>To ensure optimal clinical sensitivity and specificity, comprehensive panel-based reflexive testing based on the predominant neurological phenotypic presentation (e.g., encephalopathy) is ideal in the workup of cases of suspected autoimmune neurological disease. Predictive scores based on the clinical workup can aid in deciding when to order a test. Testing of both CSF and serum is recommended with few exceptions. Appropriate test ordering and interpretation requires an understanding of both testing methodologies and performance of antibody testing in different specimen types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review discusses important considerations in the design and selection of neural antibody testing methodologies and panels. Increased collaboration between pathologists, laboratorians, and neurologists will lead to improved utilization of complex autoimmune neurology antibody testing panels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaa254","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T15:13:02Z","timestamp":1604329982000},"page":"1496-1509","source":"Crossref","is-referenced-by-count":79,"title":["Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis"],"prefix":"10.1093","volume":"66","author":[{"given":"Adrian","family":"Budhram","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"},{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liju","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Bhayana","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"},{"name":"Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"2021070216531888000_hvaa254-B1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-444-63432-0.00010-4","article-title":"Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment","volume":"133","author":"Pittock","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2021070216531888000_hvaa254-B3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/epi.14649","article-title":"Antibody prevalence in epilepsy and encephalopathy score: increased specificity and applicability","volume":"60","author":"Dubey","year":"2019","journal-title":"Epilepsia"},{"key":"2021070216531888000_hvaa254-B5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","article-title":"Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction","volume":"323","author":"Dubey","year":"2018","journal-title":"J Neuroimmunol"},{"key":"2021070216531888000_hvaa254-B6","doi-asserted-by":"crossref","first-page":"E529","DOI":"10.1503\/cmaj.181548","article-title":"Diagnosing autoimmune limbic encephalitis","volume":"191","author":"Budhram","year":"2019","journal-title":"CMAJ"},{"key":"2021070216531888000_hvaa254-B7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.25655","article-title":"Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune lgi1\/caspr2 epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"2021070216531888000_hvaa254-B10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"2021070216531888000_hvaa254-B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24979","article-title":"Expanded phenotypes and outcomes among 256 lgi1\/caspr2-igg-positive patients","volume":"82","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B13","doi-asserted-by":"crossref","first-page":"S20.002","DOI":"10.1212\/WNL.88.16_supplement.S20.002","article-title":"Specificity of glial fibrillary acidic protein igg autoantibody (GFAP-IgG) for autoimmune meningoencephalomyelitis diagnosis (s20.002)","volume":"88","author":"Flanagan","year":"2017","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A new classification system for igg4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"2021070216531888000_hvaa254-B15","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021070216531888000_hvaa254-B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","article-title":"Anti-hu-associated paraneoplastic encephalomyelitis\/sensory neuronopathy. A clinical study of 71 patients","volume":"71","author":"Dalmau","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"2021070216531888000_hvaa254-B18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.50.3.652","article-title":"Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies","volume":"50","author":"Lucchinetti","year":"1998","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-444-63432-0.00009-8","article-title":"Detection methods for neural autoantibodies","volume":"133","author":"Waters","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2021070216531888000_hvaa254-B21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.1127","article-title":"ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity","volume":"50","author":"Chan","year":"2001","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","article-title":"Crmp-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity","volume":"49","author":"Yu","year":"2001","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.10518","article-title":"Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments","volume":"53","author":"Pittock","year":"2003","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/brain\/awh203","article-title":"Clinical analysis of anti-MA2-associated encephalitis","volume":"127","author":"Dalmau","year":"2004","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ana.20529","article-title":"Amphiphysin autoimmunity: paraneoplastic accompaniments","volume":"58","author":"Pittock","year":"2005","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B26","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/archneurol.2011.128","article-title":"Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond","volume":"68","author":"McKeon","year":"2011","journal-title":"Arch Neurol"},{"key":"2021070216531888000_hvaa254-B28","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1212\/WNL.0b013e318296e9c3","article-title":"Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer","volume":"80","author":"Honnorat","year":"2013","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.24872","article-title":"Microtubule-associated protein 1b: novel paraneoplastic biomarker","volume":"81","author":"Gadoth","year":"2017","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.0000000000003586","article-title":"Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies","volume":"88","author":"Do","year":"2017","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2015.11.009","article-title":"Pitfalls in the detection of CV2 (CRMP5) antibodies","volume":"290","author":"Sabater","year":"2016","journal-title":"J Neuroimmunol"},{"key":"2021070216531888000_hvaa254-B32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1017\/cjn.2018.74","article-title":"The positive predictive value of onconeural antibody testing: a retrospective review","volume":"45","author":"Budhram","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"2021070216531888000_hvaa254-B33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/73.12.1161","article-title":"Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus","volume":"73","author":"Walikonis","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"2021070216531888000_hvaa254-B34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/81.9.1207","article-title":"Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction","volume":"81","author":"Pittock","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"2021070216531888000_hvaa254-B35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"2021070216531888000_hvaa254-B36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/01.WNL.0000041495.87539.98","article-title":"Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease","volume":"60","author":"Bernal","year":"2003","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.23550","article-title":"Identification of delta\/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration","volume":"71","author":"de Graaff","year":"2012","journal-title":"Ann Neurol"},{"key":"2021070216531888000_hvaa254-B38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients","volume":"81","author":"Hoftberger","year":"2013","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"2021070216531888000_hvaa254-B40","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B41","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","article-title":"Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients","volume":"84","author":"Hoftberger","year":"2015","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B43","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0000000000002476","article-title":"Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes","volume":"86","author":"Lopez-Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B44","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-iglon5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B46","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B47","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mglur5 antibodies: symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B48","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1212\/NXI.0000000000000552","article-title":"GABAa receptor autoimmunity: a multicenter experience","volume":"6","author":"O'Connor","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B49","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in perm and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonzalez","year":"2014","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B50","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1212\/NXI.0000000000000438","article-title":"Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders","volume":"5","author":"Hinson","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00415-018-9153-8","article-title":"Patient characteristics and outcome associations in AMPA receptor encephalitis","volume":"266","author":"Laurido-Soto","year":"2019","journal-title":"J Neurol"},{"key":"2021070216531888000_hvaa254-B52","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"2021070216531888000_hvaa254-B53","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"Iglon5 antibody: neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B54","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B55","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody-associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B57","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp-2014-308736","article-title":"Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes","volume":"86","author":"Zandi","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021070216531888000_hvaa254-B58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10072-019-04004-0","article-title":"False-positive anti-NMDA receptor antibodies in severe case of Lyme neuroborreliosis","volume":"41","author":"Knudtzen","year":"2020","journal-title":"Neurol Sci"},{"key":"2021070216531888000_hvaa254-B59","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B60","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"2021070216531888000_hvaa254-B61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"2021070216531888000_hvaa254-B62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B63","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021070216531888000_hvaa254-B64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"2021070216531888000_hvaa254-B65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N Engl J Med"},{"key":"2021070216531888000_hvaa254-B66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"key":"2021070216531888000_hvaa254-B67","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"2021070216531888000_hvaa254-B68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"key":"2021070216531888000_hvaa254-B69","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B70","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol"},{"key":"2021070216531888000_hvaa254-B71","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical flair-hyperintense lesions in anti-MOG-associated encephalitis with seizures (flames): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"Budhram","year":"2019","journal-title":"J Neurol"},{"key":"2021070216531888000_hvaa254-B72","doi-asserted-by":"crossref","first-page":"105545","DOI":"10.1016\/j.clineuro.2019.105545","article-title":"The use, misuse and abuse of paraneoplastic panels in neurological disorders. A retrospective study","volume":"186","author":"Zidan","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"2021070216531888000_hvaa254-B73","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.0000000000008178","article-title":"Reader response: unintended consequences of mayo paraneoplastic evaluations","volume":"93","author":"Brier","year":"2019","journal-title":"Neurology"},{"key":"2021070216531888000_hvaa254-B74","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3389\/fneur.2019.01385","article-title":"Autoantibody diagnostics in neuroimmunology: experience from the 2018 Italian neuroimmunology association external quality assessment program","volume":"10","author":"Gastaldi","year":"2019","journal-title":"Front Neurol"},{"key":"2021070216531888000_hvaa254-B75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ajcp\/82.1.57","article-title":"Standardization of the immunofluorescence test for autoantibody to nuclear antigens (ANA): use of reference sera of defined antibody specificity","volume":"82","author":"Molden","year":"1984","journal-title":"Am J Clin Pathol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/12\/1496\/38853330\/hvaa254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/12\/1496\/38853330\/hvaa254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T16:27:54Z","timestamp":1723825674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/66\/12\/1496\/5998366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,22]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaa254","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,11,22]]}}}